Alterity Therapeutics: Notice of General Meeting/Proxy Form
Filed with ASX · · 29 pages · English
Summary by 6ix AI
Alterity Therapeutics Ltd. has issued a notice for an upcoming general meeting of shareholders, which will be held online. The meeting will address several resolutions, including the election of directors and a proposed consolidation of capital. Shareholders are encouraged to submit questions in advance and to vote by proxy if they cannot attend the meeting. The notice includes details on how to participate in the virtual meeting and the importance of shareholder votes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
- Alterity Receives Positive FDA Feedback on CMC Meeting
- Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
- Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
Later from Alterity Therapeutics
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- FDA Meeting Minutes Confirm Registrational Path for ATH434
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics